Finvest
CORT Biotechnology · Commercial biotech · Cortisol modulators · Oncology launch · Thesis updated June 14, 2026

A one-drug story starts to diversify

01 Running thesis

Diversification is finally real

Corcept used to be almost all Korlym. That made the company simple, but also fragile. In March 2026, the FDA approved Lifyorli for platinum-resistant ovarian cancer, and Corcept began selling it in April. That turns Corcept from a Cushing's syndrome company into a company with two commercial franchises.

The early Lifyorli launch looks better than feared. Management said prescriptions were written by over 200 physicians in the first 36 days of launch. Lifyorli was also added to NCCN cancer treatment guidelines as a preferred regimen 15 days after approval, which can help doctors and insurers adopt it faster.

The bull case is that Lifyorli ramps quickly, Korlym demand turns into reported revenue once payer and pharmacy backlogs clear, and the market gives more credit to Corcept's oncology pipeline. The relacorilant Cushing's program also moved back into FDA review after a June 2026 NDA resubmission, giving investors a clearer next event.

The bear case is still serious. Korlym faces generic pressure after Corcept lost its Teva patent appeal in February 2026. SG&A spending jumped to support launches, and Q1 2026 showed a net loss. If Lifyorli sales build slowly or the FDA again requires more work for relacorilant in Cushing's syndrome, the stock's low valuation score will matter.

Jun 2026▲Corcept resubmitted the relacorilant NDA for Cushing's syndrome after the FDA's December 2025 rejection. This gives the program a clearer path and likely shifts the next major readout to the FDA review cycle.
Apr 2026▲Management raised 2026 revenue guidance to $950 million to $1.05 billion. Early Lifyorli adoption was strong, with prescriptions from over 200 physicians in the first 36 days.
Apr 2026→Q1 2026 revenue rose to $164.9 million, but SG&A rose sharply to support commercialization. Korlym prescriptions hit records, while insurance and pharmacy backlogs delayed some revenue recognition.
Feb 2026▼The 2025 10-K captured two major hits: the FDA rejected relacorilant for Cushing's syndrome, and Corcept lost its final Teva patent appeal. The positive offset was strong ovarian cancer data for relacorilant.
Nov 2025→The thesis stayed centered on Korlym defense and relacorilant execution. Pharmacy capacity was improving, but the SG&A build for future launches raised execution risk.
Jul 2025▲Corcept submitted the ovarian cancer NDA for relacorilant in July 2025. That moved a second possible revenue stream closer to market.
02 Business model

Specialty drugs fund the pipeline

Corcept makes money by selling specialty medicines in the United States. Korlym and its authorized generic treat high blood sugar in adults with endogenous Cushing's syndrome. Lifyorli, the same active drug as relacorilant, is sold with nab-paclitaxel for certain ovarian cancer patients.

Q1 2026 net product revenue was $164.9 million, up from $157.2 million a year earlier. The filing said sales volume rose 12.4 percent, but average price fell 6.7 percent because more volume came from the authorized generic version of Korlym.

The model works best when specialty pharmacies, insurers, and doctors move patients through the system quickly. Q1 demand was strong, but revenue lagged because of annual insurance reauthorizations and pharmacy prior authorization backlogs. Management expects those prescriptions to show up more fully in later quarters.

Costs are rising with the bigger ambition. SG&A expense was $145.4 million in Q1 2026, versus $90.7 million a year earlier, mainly to support hypercortisolism products and Lifyorli. That spending is sensible if two launches work, but painful if either one misses.

03 Product portfolio

Korlym pays, Lifyorli grows

Cash cow

Korlym

Korlym treats hyperglycemia in adult patients with endogenous Cushing's syndrome. It remains the main revenue base, but it faces generic pressure.

Steady

Authorized generic Korlym

Corcept launched an authorized generic in June 2024. It helped defend volume, but it also lowers average selling price.

Growth engine

Lifyorli

Lifyorli was approved in March 2026 for certain platinum-resistant ovarian cancer patients and launched in April 2026. Early physician use and NCCN guideline support make it the key new growth driver.

Option

Relacorilant for Cushing's syndrome

The FDA rejected the Cushing's NDA in December 2025, saying more evidence of efficacy was needed. Corcept resubmitted the NDA in June 2026 after further analyses of existing data.

Option

Miricorilant for MASH

Miricorilant is being studied for MASH, a liver disease linked to fat buildup and inflammation. Enrollment in the Phase 2b MONARCH trial is complete.

Option

Dazucorilant for ALS

Dazucorilant is planned for a pivotal Phase 3 trial in ALS in 2026. This is a high-risk neurology program.

Option

Nenocorilant in oncology

Nenocorilant is being tested with nivolumab in the Phase 1b SYNERGY trial for solid tumors. It is part of Corcept's broader bet on cortisol modulation in cancer.

04 Business segments

One reported segment, two markets

Endocrinology100%modest
Oncology0%growing fast
Metabolic diseases0%flat
Neurology0%flat

Corcept reports one business segment. For the Q1 2026 period, reported revenue came from hypercortisolism products because Lifyorli sales began after quarter-end in April 2026.

05 Risk factors

What can break the story

Korlym generic erosion

High impact · High odds

Corcept lost its Teva patent appeal in February 2026. That removes an important barrier around Korlym and raises the risk of faster price and margin pressure from Teva or other generic entrants.

We watchTrack Korlym volume, average price, and any new generic launch disclosures.

Slow Lifyorli ramp

High impact · Medium odds

Lifyorli started well, with over 200 prescribers early in the launch and preferred NCCN guideline status. The next test is revenue, not interest. If payer access, patient starts, or gross-to-net discounts disappoint, Lifyorli may not offset Korlym pressure.

We watchWatch Q2 and Q3 2026 Lifyorli sales, prescriber growth, payer access, and gross-to-net commentary.

Cushing's resubmission setback

High impact · Medium odds

The FDA issued a Complete Response Letter for relacorilant in Cushing's syndrome in December 2025. Corcept resubmitted the NDA in June 2026 after additional analyses, but the agency could still ask for more data or another trial.

We watchWatch for FDA acceptance details, review timing, and the expected action date around mid-December 2026.

Launch spending outruns revenue

Medium impact · Medium odds

SG&A expense rose to $145.4 million in Q1 2026 from $90.7 million a year earlier. That spending supports the Lifyorli and hypercortisolism launches. If sales do not ramp fast enough, profits and cash flow could stay under pressure.

We watchCompare quarterly revenue growth against SG&A and R&D spending.

Legal overhang

Medium impact · Medium odds

Corcept faces an antitrust lawsuit from Teva and others, plus a securities class action tied to statements about the relacorilant Cushing's NDA. These cases can cost money, take management time, and hurt investor trust.

We watchWatch court filings, settlement talks, and any reserve or expense disclosure in filings.
06 Quick answers

In one breath

What does Corcept Therapeutics do?

Corcept develops and sells medicines that block or modulate cortisol, a hormone tied to stress and metabolism. Its main commercial products are Korlym for Cushing's syndrome and Lifyorli for ovarian cancer.

Why does Lifyorli matter so much for CORT stock?

Lifyorli is Corcept's first real revenue source outside Korlym. If it ramps well, Corcept becomes less dependent on a drug that faces generic competition.

What happened with relacorilant in Cushing's syndrome?

The FDA declined to approve it in December 2025 and asked for more evidence of efficacy. Corcept resubmitted the NDA in June 2026 after additional analyses of existing clinical data.

Is Corcept still dependent on Korlym?

Yes, for now. Q1 2026 reported revenue still came from hypercortisolism products, since Lifyorli sales began after quarter-end in April 2026.